For Tuesday, September 27th
EMDHB, MNDP, MELA, COIN, MRNA, EGOH
Our Stocks to Watch tomorrow include bNet Communications Inc. (OTCBB: EMDHB), Mundus Group Inc. (OTC: MNDP), MELA Sciences (NASDAQ: MELA), Converted Organics Inc. (OTCBB: COIN), Marina Biotech Inc. (NASDAQ: MRNA) and Eagle Oil Holding Company Inc. (OTC: EGOH).
EMERGING MEDIA HOLDINGS INCORPORATED (OTCBB: EMDHB)
"Up 133.33% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/EMDHB.php
Emerging Media Holdings Inc., through its subsidiaries, engages in radio and television broadcasting in the Republic of Moldova. The company produces and broadcasts television programs and news reports primarily for the Moldovan viewing audience. It operates its own television channel TV7 that broadcasts various programs. Emerging Media Holdings Inc. produces and broadcasts in-house production programs comprising news, and various analytical programs and weather forecasts in Russian and Romanian languages. It also has contracts with the Russian television companies, NTV and NTV World, to broadcast NTV programs. In addition, the company offers programs produced by the TNT channel. Further, it involves in the construction of roads and highways, as well as surface and underground railway construction, other special construction projects, relocation services, and merchandise transportation activities in Romania. The company was founded in 1998 and is based in Oviedo, Florida.
September 26 - bNET Communications, Inc. enters into LOI with Emerging Media Holdings
Online Media Company Expands into TV Production and Broadcasting Operations
bNet Communications, Inc. (OTCBB: EMDHB) announces that it has entered into a letter of intent with Emerging Media Holdings, Inc. (“EMH”) to sell all of its digital media library, GoMO News, Ltd., and certain other intellectual property in exchange for a controlling interest in EMH .
In connection with the proposed transaction, EMH will also appoint a current member of bNet’s board of directors to EMH’s board of directors. The proposed transaction will be subject to a definitive agreement and will be submitted with the required regulatory authorities and be subject to shareholder approvals.
EMH will continue to operate its TV production and broadcasting operations in the Republic of Moldova, which is located between Romania and Ukraine in Eastern Europe. EMH’s primary TV production and broadcasting operations are the television station TV7, and the rebroadcast of TNT Bravo and the Disney channel.
bNet provides professional video and media over IP-based networks for emerging technology companies and has compiled a vast digital library of information from various business sectors. Over the last ten years, bNET has amassed a library of more than 25,000 interviews and 5,000 hours of live conference coverage.
MUNDUS GROUP INCORPORATED (OTC: MNDP)
"Up 113.33% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/MNDP.php
The Mundus Group, Inc. is an advanced aerospace technology consortium providing patented Vertical Take Off and Landing (VTOL) technology for experimental aircraft and Unmanned Air Vehicles (UAV) since 1990 through its fully owned VTOL division, Roadable Aircraft International (RAI). Mundus is at the cutting edge of jet turbine-ducted fan technology and fuses state of the art design engineering and a prototyping facility with computer assisted auto flight technologies, Remote Controlled (RC) and composite technologies industry segments. From US Navy co-developed UAVs for aerial observation and environmental testing to advanced VTOL aerospace technology for civilian and military uses, Mundus Group, Inc. is developing revolutionary products with global potential for change that offers economic protection and growth opportunities for investors.
September 23 - Mundus Group, Inc., an Aerospace UAS VTOL Technology Consortium, Announces Strategic Partnership
Whirly Bird Films Aerial Cinematography Operations to Use Mundus Air Drone UAV Electric Drone Exclusively to Shoot the Stars
Mundus Group, Inc. (OTC: MNDP) announces strategic partnership with Whirly Bird Films. In 2003, Whirly Bird Co Founder and founder of Chapman Aerospace, Justin Chapman worked with the U.S. Navy and Roadable Aircraft Inc. a Mundus Group, Inc. (MNDP) subsidiary, as a consultant for RAI on a UAV VTOL (Vertical Take Off and Landing Vehicle) Ducted Fan Project under a 3 year Co-Operative Research and Development Agreement at the Naval Air Warfare Center Weapons Division in Point Mugu, California. Since 2004, Justin Chapman has designed and built cutting edge UAV technology and has won more than 50 RC helicopter contests. In 2007, he beat the current RCX F3C World Champion, taking 1st place at the F3C World Competition.
In 2008, Chapman partnered with Wink Roberts to create Whirly Bird Films. Together, they developed and built the high-tech, high-speed camera ship known as The Cinema Flyer 3C. Having spent most of his life either in front of the camera or behind it, Whirly Bird Co founder Wink Roberts brings a unique vision to action photography. Roberts combined his talents in business management with his passions for extreme sports, performing stunts, action writing, and RC helicopters. He joined forces with Justin Chapman to create Whirly Bird Films in Hollywood, California; with one mission in mind: to design a new platform to get shots that would leave audiences asking, "How'd they do that?"
MELA SCIENCES INCORPORATED (NASDAQ: MELA)
"Up 55.03% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/MELA.php
MELA Sciences is a medical technology company focused on developing MelaFind®. MelaFind® is a non-invasive and objective multi-spectral computer vision system designed to aid physicians in the detection of early melanoma from among clinically atypical (those having one or more clinical or historical characteristics of melanoma, such as asymmetry, border irregularity, color variegation, diameter greater than 6 millimeters, evolving, patient concern, regression, and ugly duckling) cutaneous pigmented lesions that are non-ulcerated, not bleeding, and less than 2.2 centimeters in diameter, when a physician chooses to obtain additional information before making a final decision to biopsy to rule out melanoma.
September 26 - MELA Sciences Receives Approvable Letter From FDA for MelaFind®
Company to Finalize Labeling, Training Program and Clinical Protocol for Post-Approval Study; Conference Call Scheduled for 8:30 a.m.
MELA Sciences (NASDAQ: MELA) announced that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter for the MelaFind® Pre-Market Approval (PMA) application. The company intends to work with the agency to finalize the physician and patient labeling, package insert, user's guide, training program and clinical protocol for a post-approval study in order to obtain final approval.
"The FDA's Approvable Letter for MelaFind represents a monumental milestone for MELA Sciences and the millions of Americans who are at risk of developing melanoma, the deadliest form of skin cancer," said Joseph V. Gulfo, MD, President and CEO, MELA Sciences. "The company has worked tirelessly to develop an objective tool to help dermatologists detect melanoma at its earliest, most curable stages. Although melanoma is virtually 100% curable if detected at its earliest stage, one American dies from the disease every hour. We firmly believe that MelaFind has the potential to lower those tragic numbers. We are extremely pleased with the FDA's decision and will work diligently to answer all open questions and finalize the post-market study protocol in the coming weeks."
The Approvable Letter from the FDA comes on the heels of the CE Mark for MelaFind issued earlier this month. CE Mark approval allows MelaFind to be sold across the 27 nations of the European Union.
"MelaFind has the potential to provide dermatologists with significantly more information about indeterminate pigmented skin lesions to help us when deciding on which lesions to biopsy to detect melanoma as early as possible," said Darrell S. Rigel, MD, Clinical Professor of Dermatology at New York University Medical School. "While there have been incremental improvements in imaging tools for melanoma detection, we still primarily rely on our judgment based on a visual examination to select the lesions to biopsy; data show that this is often not enough."
"Taken together, the multiple clinical trials demonstrate that MelaFind represents a significant advance and should have a positive impact on patient outcomes once it's approved and available to dermatologists," said Laura K. Ferris, MD, PhD, Assistant Professor of Dermatology and Director of the University of Pittsburgh Department of Dermatology Clinical Trials Unit.
The studies used to support the PMA application for MelaFind were the 1,383 patient U.S. pivotal trial and the companion reader study of 110 dermatologists: the device demonstrated a 98% sensitivity in the pivotal trial, whereas dermatologists had a 72% sensitivity in the adjunctive reader study.
CONVERTED ORGANICS INCORPORATED (NASDAQ: COIN)
"Up 23.89% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/COIN.php
Converted Organics, Inc. focuses on the manufacture, sale, and distribution of natural soil amendment products combining nutritional and disease suppression characteristics. It uses organic food waste as raw material to manufacture soil amendment products. Converted Organics plans to sell and distribute these products in the agribusiness, turf management, and retail markets. The company was founded in 2003 and is headquartered in Boston, Massachusetts.
August 16 - Converted Organics Announces 2011 Year-To-Date and Second Quarter Financial Results and Schedules Shareholder Conference Call
Shareholder Conference Call to be held on Wednesday, August 17, 2011 at 10 AM ET
Converted Organics Inc. (OTCBB: COIN) announced that it had sales for the three months ended June 30, 2011 of $1,429,000 and income for the three months of $1,098,000 compared to sales of $1,245,000 and a loss of $3,325,000 for the same quarter last year. For the six months ended June 30, 2011 the Company reported sales of $2,169,000 and a loss of $649,000 compared to sales of $1,957,000 and a loss of $9,705,000 for the same period last year. Income generated in the quarter ended June 30, 2011 is attributable to gains on debt and equity transactions. Further detail is available in the Company's Form 10-Q which was filed on August 15, 2011 and will be discussed during the Company's shareholder conference call which is scheduled for Wednesday, August 17, 2011 at 10:00 AM EST.
"We are pleased with our results for 2011 overall which show increased sales and operating margins, and with our progress in developing our businesses. Profits in the second quarter were attributable to gains on debt and equity transactions related to share price fluctuations, however, we are confident that we are completing the restructuring process, which we began in 2010, and we are continuing to position the business to grow organically through acquisitions and other transactions," said Edward Gildea, president of Converted Organics.
Converted Organics has scheduled a conference call on Wednesday, August 17, 2011 at 10:00 AM ET to update shareholders on recent business developments and discuss the Company's results for the quarter ended June 30, 2011.
MARINA BIOTECH INCORPORATED (NASDAQ: MRNA)
"Up 12.33% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/MRNA.php
Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs — in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies that together provide superior therapeutic options for patients.
September 26 - Breakthrough Intranasal Insulin Delivery Formulations for Sale Through ICAP Patent Brokerage
ICAP Patent Brokerage, a division of ICAP plc, the world's largest intellectual property brokerage and patent auction firm, is offering for sale a patent portfolio related to rapid-acting intranasal (IN) insulin delivery formulations. The patent portfolio is owned by Marina Biotech, Inc. (NASDAQ: MRNA).
J. Michael French, CEO of Marina Biotech, Inc. commented, "Our intranasal insulin program, originally positioned to serve a diabetic patient population, holds additional promise in the potential treatment of CNS diseases such as Alzheimer's. Our proprietary formulation may provide distinct therapeutic advantages over other intranasal delivered insulin compounds. ICAP Patent Brokerage's platform provides an opportunity to quickly capitalize on the potential of this legacy program and ensures a timely and well-managed auction process for our intranasal compound portfolio."
Key Attributes of Marina Biotech's Formulation:
* US IND is active; preclinical studies, Phase 1 and multicenter Phase 2 clinical trials have been completed, allowing a rapid path to the market
* Plasma insulin from intranasal administration crosses the blood brain barrier into the brain using the dedicated insulin transporter for potential effects on Alzheimer's and other CNS diseases
* Very rapid PK profile: works more quickly on post prandial glucose yet has a lower rate of post meal hypoglycemia compared with insulin analogs as well as a more rapid onset of action than a subcutaneously injected insulin analog
* Delivers insulin to the nasal mucosa - does not enter the lungs.
* Well tolerated by patients
* Can be formulated either with regular insulin or insulin analogs.
* Intranasal insulin formulated with regular insulin is stable at room temperature
* Published data available.
EAGLE OIL HOLDING COMPANY INCORPORATED (OTC: EGOH)
"Up 38.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/EGOH.php
Eagle Oil (EGOH) is an independent, growth-oriented energy company engaged in the exploration and production of oil through the development of a repeatable, low geological risk, high potential project in the active East Texas oil and gas region. The Company owns a 78% working interest in 173 wells on its 927 acres located in the Historic Woodbine Oil Field. The Company's goal is to recondition and restore production at all of its wells. Engineering reports show that Eagle Oil's East Texas field contains over 12,000,000 barrels of recoverable oil.
July 12 - Eagle Oil Provides Update on Questus Energy Farmout Agreement
Eagle Oil Holding Company, Inc. (OTC: EGOH) ("Company") provides the following update on the oil field restoration to be performed by Questus Energy.
Under the Farmout Agreement, Questus will perform all work and pay all costs associated with reconditioning an initial group of 15 existing oil wells in our East Texas oil field. As part of the work, which the Company expects to commence within the next two weeks, Questus will perform required fluid level and integrity tests on 33 wells located in the field as required by the Texas Railroad Commission. Once these tests are satisfactorily completed, Questus will be able to immediately restart pumping oil on five wells which are already fully equipped. Pumping will restart on the ten additional wells once they are re-equipped by Questus.
The Company expects pumping on the first five wells to commence within 45 days and all 15 wells to be in production within 60 days. The Company projects production to reach approximately 90 barrels per day once all 15 wells are reconditioned.
Additional groups of 10 wells will then be assigned to Questus, up to a total of 104 wells. The Company believes that pumping can resume at all 104 wells by November 2012.
The Company has also signed farmout agreements with two other entities for a total of up to 40 additional wells.